Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 6/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 4/20 | 0.31 |
| ▸ | CA9 | Q16790 | 4/20 | 0.31 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951580 | 0.81 | DRD2 (0.44) | ENPP2CA1CA2CA12CA9 | |
| SCHEMBL14721223 | 0.81 | DRD2 (0.39) | ENPP2CA1CA2CA12CA9 | |
| SCHEMBL16564308 | 0.81 | DRD2 (0.44) | ENPP2CA1CA2CA12CA9 | |
| SCHEMBL4621217 | 0.78 | DRD2 (0.33) | ENPP2DRD2 | |
| SCHEMBL12639825 | 0.78 | DRD2 (0.37) | ENPP2DRD2 | |
| SCHEMBL3963273 | 0.77 | MAPT (0.42) | CA1CA12CA9 | |
| SCHEMBL14992971 | 0.77 | HTR2A (0.36) | CA1CA12CA9 | |
| SCHEMBL15332756 | 0.76 | TTR (0.33) | TTRENPP2 | |
| SCHEMBL15770495 | 0.75 | ENPP2 (0.35) | ENPP2DRD2 | |
| SCHEMBL1018126 | 0.74 | ENPP2 (0.49) | TTRENPP2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3981839-B1 | COELENTERAZINE ANALOGS FOR USE IN LUCIFERASE-BASED ASSAYS | PROMEGA CORP (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2024-02-22 | — | — | US | disclosed |
| US-11691976-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| EP-3841173-A1 | COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2021-06-30 | — | — | EP | disclosed |
| CN-112513188-A | Coelenterazine analogs | 普洛麦格公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-02-27 | — | — | US | disclosed |
| WO-2020041579-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | TTR 3319/4885ENPP2 888/4885CA1 2504/4885 |
| US-11691976-B2 | Coelenterazine analogues | GLB1, SI, TCF7L2 | TTR 3319/4885ENPP2 888/4885CA1 2504/4885 |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | TTR 3319/4885ENPP2 888/4885CA1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.